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Abstract: Anakinra is an interleukin (IL) receptor antagonist that works by blocking the 
biological activity of IL-1 by competitively inhibiting binding of IL-1 to the type 1 interleukin 
receptor. IL-1 production is induced in response to inflammatory stimuli and mediates various 
physiological mechanisms, including inflammation and immunological reactions. Patients with 
neonatal onset multisystem inflammatory disease (NOMID) produce excess IL-1β, a major 
proinflammatory cytokine that regulates innate immune responses. Anakinra binds competitively 
and this results in a rapid reduction in disease severity. NOMID, also known as chronic infantile 
neurologic, cutaneous, articular syndrome, is the most severe clinical phenotype in the spec-
trum of cryopyrin-associated periodic syndromes. It is characterized by cutaneous symptoms, 
arthropathy, and central nervous system involvement. Extensive studies in patients with NOMID 
have led to advances in characterizing the extent of organ-specific involvement and damage that 
occurs with chronic overproduction of IL-1β. NOMID is caused predominantly by mutations 
in the NLRP3/CIAS1 gene that encodes for the protein cryopyrin, leading to activation of the 
“NLRP3 inflammasome complex”. This in turn regulates the maturation and secretion of the 
inflammatory cytokine, IL-1β. The clinical value of IL-1β has been demonstrated by the positive 
response of patients after treatment with anakinra, with rapid improvement in clinical symptoms, 
markers of inflammation, and a significant decrease in major organ manifestations.
Keywords: neonatal onset multisystem inflammatory disease, chronic infantile neurologic, 
cutaneous, arthritis syndrome, NLRP3, CIAS1, interleukin-1β
Introduction
Neonatal onset multisystem inflammatory disease (NOMID) is a monogenic autoin-
flammatory syndrome and constitutes one of the three known cryopyrin-associated peri-
odic syndromes (CAPS). These syndromes occur as a result of an autosomal dominant 
or de novo mutation of the cold-induced autoinflammatory syndrome 1 (CIAS1) gene 
on chromosome 1q44.1 The three clinical entities that belong to the group of diseases 
known as CAPS were discovered at different times, and initially described separately as 
distinct diseases. It was not until a common genetic defect was identified that these 
three diseases were recognized as separate clinical phenotypes of the same disease 
mechanism. The three forms of CAPS are familial cold autoinflammatory syndrome 
(FCAS), Muckle–Wells syndrome (MWS), and NOMID, or as it is known in Europe, 
chronic infantile neurological, cutaneous, articular (CINCA) syndrome. The discovery 
of a common etiology for these diseases is an important step in the understanding 
of autoinflammatory disease. The clinical spectrum, including both similarities and 
differences in presentation of the three diseases, adds to the intrigue surrounding the 
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Table 1 Similarities and differences between CAPS with symptom progression from the mildest form to the most severe form of the 
disease
FCAS MWS NOMID/CINCA
Severity Low Medium High
Triggers Cold-induced None None
Fever/rash Usually daily symptoms variable symptoms (rare to daily) variable symptoms (rare fever, daily rash)
Joint involvement Arthralgia Arthralgia/arthritis Arthralgia, arthritis, overgrowth arthropathy
Neurological involvement None None Chronic aseptic meningitis (headache,  
mental retardation)
eye involvement Conjunctivitis Conjunctivitis, uveitis Uveitis, papillary edema, optic neuritis
Hearing loss None Frequent (60%) Frequent (.60%)
Amyloidosis No Frequent (25%) Frequent (25%)
inheritance Autosomal dominant Autosomal dominant or  
de novo (rare)
De novo (typical) or autosomal dominant  
(rare)
Pathophysiology Mutation in CIAS1 gene 
encoding for cryopyrin
Mutation in CIAS1 gene encoding  
for cryopyrin
Mutation in CIAS1 gene encoding for  
cryopyrin
Treatment Anti-iL-1 therapy Anti-iL-1 therapy Anti-iL-1 therapy
Abbreviations: IL, interleukin; FCAS, familial cold autoinflammatory syndrome; MWS, Muckle–Wells syndrome; NOMID, neonatal onset multisystem inflammatory disease; 
CiNCA, chronic infantile, neurological, cutaneous, articular syndrome; CAPS, cryopyrin-associated periodic syndromes.
common genetic defect. Why does a single common defect 
lead to such diverse clinical symptoms and signs?
Along the clinical spectrum of CAPS, all three diseases 
present in the neonatal period, although there have been 
reports of presentation after infancy and even into adulthood. 
Common features of these diseases include inflammation 
of the skin, eyes, bones, joints, and meninges. In addition, 
severe fatigue, fever, myalgia, chronic anemia, and learn-
ing disabilities are some of the other symptoms which are 
commonly seen.2 The similarities and differences of these 
diseases are shown in Table 1. These diseases make up a 
group of rare hereditary autoinflammatory diseases, with 
an estimated population frequency in the range of 1–3 per 
million.3
The discovery of a genetic basis for these disorders has 
significantly impacted new approaches to treatment. The 
CIAS1 gene, which is mutated in CAPS patients, has been 
discovered to be involved in inflammation and apoptosis.4 
In response to inflammation, interleukin (IL)-1β is secreted 
and is known to mediate the peripheral immune response 
during infection and inflammation. It has been reported 
that patients with NOMID and other CAPS disorders have 
higher IL-1β levels compared with their healthy counter-
parts. Thus, the mutation in CAPS is a gain-of-function 
mutation.
As a result of the pathogenesis, targeting the IL-1β path-
way has proven to be a successful approach in the treatment 
of patients with CAPS, specifically NOMID. Recent advances 
in the development of drugs targeting IL-1β have led to the 
introduction of several anti-IL-1β drugs, including anakinra, 
rilonacept, and canakinumab.
Cryopyrin-associated periodic 
syndromes
The three cryopyrin-associated periodic syndromes are 
FCAS, MWS, and NOMID. Chronic inflammation, with 
recurrent fever, cutaneous rash, and joint symptoms, are com-
mon characteristics of these diseases. As they progress from 
the mildest form to the most severe form, the rash becomes 
less prominent, and other more severe features dominate 
the clinical presentation.5 This spectrum of disease severity 
is shown in Table 1.
Familial cold autoinflammatory syndrome
FCAS is the mildest phenotype of the autoinflammatory 
diseases and is characterized by urticarial rash, low grade 
fever, polyarthralgias, and conjunctivitis induced by exposure 
to cold, occurring primarily in infancy.6 These episodes are 
generally self-limiting and resolve within 24 hours. Other 
symptoms induced by cold exposure include profuse sweating, 
drowsiness, headache, extreme thirst, and nausea.7 Although 
these symptoms have a significant impact on quality of life, 
they are not associated with organ damage or  disability. 
 Laboratory studies show elevated neutrophil counts, eryth-
rocyte sedimentation rate, and C-reactive protein.
Muckle–wells syndrome
MWS is the intermediate phenotype and is characterized by 
recurrent episodes of rash and fever that may develop in the 
first few years of life. The rash can be cold-induced, urti-
carial, or erythematous. Musculoskeletal symptoms include 
arthralgia, arthritis, and myalgias. These features occur 
episodically and can last anywhere from one day to 2 weeks. 
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Sequelae of MWS may include sensorineural hearing loss and 
secondary renal amyloidosis with nephropathy (a complica-
tion of late stage disease).8 The hearing loss is progressive, 
likely leading to deafness by adolescence, and the amyloi-
dosis may progress to impaired renal function. Laboratory 
findings include generalized leukocytosis and elevations in 
acute-phase reactants.
Neonatal onset multisystem  
inflammatory disease
NOMID is the most severe phenotype, with the course of 
disease being more chronic than recurrent. It manifests in the 
first few weeks of life with an urticarial-like rash, arthropathy, 
and central nervous system involvement.9 The rash is typically 
nonpruritic and can vary with disease activity. Fever is usu-
ally mild in this disease. Individuals have atypical “facies”, 
including frontal bossing, a saddle-back nose, and mid-face 
hypoplasia. The disease also causes bony overgrowths pre-
dominantly involving the knees and the distal extremities of 
the hands and feet. Chronic inflammatory polyarthritis may 
also be present, resulting in bone erosions. The severity of 
bone and joint involvement is variable, with approximately 
two thirds of patients developing arthralgia and transient 
swelling during flares, and the remaining one third developing 
severe and disabling arthropathy, resulting in gross deformity 
of the patella and epiphyses of the long bones.10
The radiographic findings in severe cases are characterized 
by a “bread crumb” appearance of the patella and epiphyses. 
Central nervous system manifestations can be the most dev-
astating, and include chronic septic meningitis, increased 
intracranial pressure, cerebral atrophy, ventriculomegaly, 
sensorineural hearing loss, and chronic papilledema with 
associated optic nerve atrophy and loss of vision. Mental 
retardation and seizures are also present.9
Findings suggestive of an ongoing inflammatory process 
include lymphadenopathy, splenomegaly, elevations in 
acute-phase reactants (erythrocyte sedimentation rate and 
C-reactive protein), leukocytosis, cerebrospinal fluid neu-
trophilia, hyperglobulinemia, and chronic anemia. Failure 
to control the inflammation can lead to irreversible organ 
damage and disability. Therefore, it is imperative to start 
treatment as soon as the disease is suspected.
Pathophysiology  
of autoinflammatory syndromes
Genetics of cryopyrin
The discovery of a genetic basis for NOMID has led to its 
placement among the other cryopyrinopathies, all of which 
are caused by mutations in the CIAS1 gene. The genetic 
defect was first defined in FCAS in 2000, and subsequently 
the same gene was found to be responsible for MWS.7,11 The 
genetic defect was identified in NOMID in 2002. There are 
many mutations that lead to CAPS, and are located in exon 3 
of the CIAS1 gene. All are gain-of-function mutations and 
are essential to the activation of intracellular caspase-1 and 
processing of IL-1β.12
Mechanism of action of cryopyrin
CIAS1 encodes the cryopyrin molecule, which combines with 
a group of interacting proteins to form a macromolecular com-
plex called the “inflammasome,” that is important in the innate 
immune response due to its role as a molecular platform.13 
There are at least four inflammasomes, designated NLRP1, 
NLRP3, NLRC4, and AIM2.14 The NLRP3 inflammasome, 
which is directly responsible for CAPS, contains three separate 
components that are all involved in the  activation of proinflam-
matory cytokines, such as IL-1β and IL-18. These components 
include NLRP3/cryopyrin, an apoptosis-associated speck-like 
protein (ASC) containing a CARD (caspase activation and 
recruitment domain) and a leucine-rich repeat domain.
The signals leading to inflammasome activation and gen-
eration of proinflammatory cytokines such as IL-1β include 
danger-associated molecular patterns and pathogen-associated 
molecular patterns. There have been many danger-associated 
molecular patterns described, including cholesterol or uric acid, 
toxins, adenosine triphosphate (ATP), and ultraviolet B radia-
tion.15–17  Pathogen-associated molecular patterns that have been 
shown to activate NALP3 include bacteria such as Neisseria 
gonorrhea and viruses such as Influenza A.18,19 Once NLRP3 is 
stimulated, it oligomerizes and binds the adaptor protein ASC. 
ASC interacts with cryopyrin, leading to activation of nuclear 
factor kappa B and caspase-1, and apoptosis.20
Activation of caspase-1 results in cleavage of pro-IL-1β 
and pro-IL-18 into their mature forms (IL-1β and IL-18, 
respectively) which are secreted by the cell.21 Thus, activated 
cryopyrin induces release of the active form of IL-1β. This 
process is illustrated in Figure 1. In all three phenotypes 
of CAPS, the gain-of-function mutation of the NLRP3 
gene forms a defect in this pathway, resulting in increased 
inflammasome activation, which enhances and accelerates 
production of IL-1β, leading to the inflammatory symptoms 
seen in NOMID.22
Therapeutic targets and strategies
The disorders caused by CIAS1 mutations are not distinct 
diseases, but represent a clinical continuum of phenotypes. 
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It was discovered that the same nucleotide substitution in 
CIAS1 may be associated with a different clinical subtype in 
different patients.23 It is also interesting that various mutations 
in CIAS1 result in different levels of caspase-1 activation, 
thereby leading to such extreme clinical spectrum ranges 
as seen in the different phenotypes of CAPS.24 In addition, 
CIAS1 mutations may not always be the culprit in diseases 
involving cryopyrin. This has been evident in several patients 
with FCAS, MWS, and NOMID who do not have mutations 
in CIAS1, but have the classic disease phenotype.
Most CIAS1 mutations are inherited in an autosomal 
dominant pattern, although de novo cases have been reported. 
Mutations in CIAS1 were found in 50% of NOMID patients 
and mutations occurred de novo in five of seven patients with 
NOMID syndrome.25 This suggests that the severity and pres-
ence of the disease is likely to be influenced by other genetic 
and environmental factors.26
The CIAS1 mutation in CAPS is a gain-of-function 
mutation in cryopyrin, leading to activation of proinflamma-
tory cytokines. IL-1, one of the proinflammatory cytokines 
activated in CAPS, is the primary target for drugs such as 
 anakinra. It was originally thought that anakinra should be 
used in the treatment of NOMID patients with CIAS1 muta-
tions only. However, a number of studies have demonstrated 
that anakinra is effective for treatment of the disease regard-
less of the gene defect present. For example, recent work by 
The NLRP3 inflammasome
NLRP3 or
cryopyrin
(CIAS1) 
ASC
(PYCARD) 
LRR 
Pro-caspase 
Caspase and
NFκB
Pro 
IL-1β
IL-1β
IL-18 
CAPS 
DAMPs
External ATP
Uric acid
Cholesterol 
Toxins
UVB radiation  
PAMPs
Neisseria gonorrhea
Influenza A
Anakinra  
Figure 1 Pathophysiology of CAPS. Activation of the NLRP3 inflammasome is triggered by exposure of immune cells to a variety of danger-associated molecular patterns 
and pathogen-associated molecular patterns. The leucine-rich repeat domain of the NLRP3 is thought to serve as an autoinhibitor by self-folding. The molecule spreads out, 
dimerizes, and associates through homotypic interaction with the ASC adaptor protein to mediate the proteolytic processing of pro-caspase 1 to caspase-1. The ASC protein 
also interacts with cryopyrin. when cryopyrin binds to ASC it can result in NFκB and caspase-1 activation. Once caspase-1 is activated, it results in cleavage of pro-iL-1β and 
pro-iL-18 into their mature forms iL-1β and iL-18, respectively, which is secreted by the immune cell. Thus, activated cryopyrin induces release of the active form, iL-1β.
Abbreviations: DAMPs, danger-associated molecular patterns; PAMPs, pathogen-associated molecular patterns; iL, interleukin; ASC, apoptosis-associated speck-like 
protein; CAPS, cryopyrin-associated periodic syndromes; UvB, ultraviolet B; LRR, leucine-rich repeat; ATP, adenosine triphosphate.
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Lovell et al demonstrated improvement of NOMID symptoms 
in a patient with a normal CIAS1 gene sequence after treat-
ment with anakinra.27 In another study by Hawkins et al, three 
patients were diagnosed with NOMID on clinical grounds and 
later revealed no CIAS1 mutations. After receiving anakinra, 
all three patients had resolution of fever, rash, joint inflamma-
tion, and headache, with normalization of C-reactive protein 
and erythrocyte sedimentation rate.28 These findings suggest 
that regardless of the upstream mechanism, such as CIAS1 
defects, correction of the downstream effect including IL-1β 
overproduction ameliorates symptoms of the disease.
Another observation has been the presence of somatic 
mosaicism in patients with CIAS1-related disease. Tanaka 
et al were able to identify that NOMID/CINCA resulted 
from the mutant NLRP3 gene in these cases of somatic 
mosaicism, in which mutant cells accounted for 4.2%–35.8% 
of all blood cells.29
Treatment
Traditional treatment
Traditional treatment of CAPS has utilized anti- inflammatory 
agents such as glucocorticoids, nonsteroidal anti-inflammatory 
agents, antihistamines, and other  immunosuppressive 
medications, all without significant success. While there 
have been modest improvements with high-dose oral cor-
ticosteroids and thalidomide, these agents have not been 
well tolerated due to their side effect profile. Because of the 
discovery that IL-1β is a potent proinflammatory cytokine 
which is upregulated by mutations in CIAS1, three new thera-
pies have been identified which use different approaches to 
achieve the same goal.
Anakinra: an iL-1 receptor antagonist
Exploration of IL-1 receptors started in 1993 with the 
introduction of anakinra, a recombinant, nonglycosylated 
version of IL-1 receptor antagonist (IL-1RA) prepared 
from cultures of genetically modified Escherichia coli using 
recombinant DNA technology. It consists of 153 amino 
acids and differs from native human IL-1RA in that it has 
the addition of a single methionine residue on its amino 
terminus. Since 1993, anakinra has been well studied and 
has been shown to control many diseases, including CAPS. 
Use of anakinra in different diseases is shown in a time-
line in Figure 2. Anakinra currently dominates the field of 
IL-1 therapeutics, mostly because of its excellent safety 
profile and tolerability by pediatric and adult patients. 
1993 – anakinra manufactured by the
pharmaceutical company Amgen, Inc.  1993 – anakinra first used in
rheumatoid arthritis  
2001 – anakinra approved by the US FDA 
for rheumatoid arthritis in patients 
18 years of age and older who have 
failed one or more DMARDs 
2007 – anakinra tested in type 2
diabetes 
2010 – anakinra used in STEMI and
CAPS 
2012 – anakinra used in heart failure  
2013 – approved by the US FDA for the
treatment of NOMID patients 
2003 – anakinra used in MWS  
2004–2006 – anakinra used in FMF 
and HIDS 
2005 – anakinra used in adult onset
Still’s disease and systemic juvenile
idiopathic arthritis   
Figure 2 Timeline highlighting use of anakinra in various disease states.
Abbreviations: CAPS, cryopyrin-associated periodic syndromes; DMARDs, disease-modifying antirheumatic drugs; US FDA, US Food and Drug Administration; FMF, 
familial Mediterranean fever; HIDS, hyper-IgD syndrome; STEMI, ST elevation myocardial infarction; NOMID, neonatal onset multisystem inflammatory disease; MWS, 
Muckle–wells syndrome.
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Anakinra was approved by the US Food and Drug Adminis-
tration in January 2013 for the treatment of NOMID, and its 
use is expected to increase, given that it may have a beneficial 
effect in other disease states.
A role for anakinra in the treatment of CAPS has been 
evident in prevention of clinical symptoms and acute-phase 
elevations in patients with FCAS,30 an ability to induce 
complete remission in MWS, and resolution of symptoms 
including uveitis, rash, and fever in NOMID patients.31,32 
The possibility of reducing the clinical symptoms of 
 inflammation and improvement in quality of life makes 
this discovery extremely important. The safety and efficacy 
of anakinra have been tested in a number of studies, with 
promising results.
The short-term efficacy and rapid response to anakinra 
was first reported in a study by Hawkins et al, who followed 
three severely ill family members carrying NALP3/CIAS1 
mutations. It was reported that clinical features such as rash, 
fever, conjunctivitis, and arthralgia improved within 4 hours 
after the first injection, and serologic remission was achieved 
within one week. The study also reported a rapid decrease 
in C-reactive protein levels and a resolution of hematologic 
abnormalities in all patients.33
Immediate resolution of clinical symptoms was also 
evident in a retrospective study by Leslie et al, who demon-
strated complete remission of rash, fever, conjunctivitis, and 
rheumatic aches within 4–12 hours of starting anakinra in 15 
patients treated for 39 months. These patients were treated 
starting with daily 100 mg subcutaneous injections and then 
reduced to 20–50 mg to determine efficacy at lower doses. 
All patients improved on the lower doses, except for two 
children who continued to receive 100 mg daily injections. 
Monthly measurements of C-reactive protein and serum 
amyloid A levels were reviewed, and demonstrated normal-
ization within one week in all patients. In addition, nephrotic 
syndrome remitted within 8–33 months in three patients with 
AA amyloidosis.34
In a prospective study, Goldbach-Mansky et al demon-
strated improvement in symptoms such as urticarial-like rash 
and acute-phase reactants, in addition to improvements in 
hearing and neurosensory deficits in 18 children with CINCA/
NOMID (12 with identifiable CIAS1 mutations) followed for 6 
months. The treatment was able to effectively control most of 
the clinical manifestations, including chronic meningitis and 
papilledema. Abnormal cochlear enhancement was detected in 
17 patients on magnetic resonance imaging, and although 13 
of these patients had improvement of cochlear enhancement, 
one had a regression and three had no improvement after 
3 months of therapy. Primary outcomes were decreases in 
C-reactive protein, erythrocyte sedimentation rate, and serum 
amyloid A levels, as well as daily improvement in ratings of 
symptoms at 3 months, all of which also remained low at 6 
months. In total, eight of 18 patients showed remission of 
inflammatory symptoms after 3 months and the remaining ten 
patients after 6 months. Furthermore, treatment with anakinra 
reduced secretion of IL-1β from cultured peripheral blood 
mononuclear cells after 6 months of therapy.32
Not only has anakinra been useful in NOMID patients, but 
it has also shown improvement in patients with other CAPS 
disorders. In a study by Kuemmerle-Deschner et al, anakinra 
proved to be an effective and safe therapy in 12 children and 
adults with severe MWS over a median of 11 (5–14) months. 
There was rapid resolution of constitutional symptoms, 
severe disease-associated fatigue, and musculoskeletal, 
skin, and eye symptoms after 2 weeks of therapy. Classical 
markers of inflammation improved in the majority of these 
patients. The erythrocyte sedimentation rate normalized in 
all but one patient (92%), and the C-reactive protein value 
normalized in 45% of those who had an elevation at baseline. 
While improvement in erythrocyte sedimentation rate was 
detectable as early as 2 weeks and then plateaued, C-reactive 
protein levels continued to improve further until the last 
follow-up visit.35
Similar observations were reported in a study by Hoffman 
et al, in which anakinra was able to prevent cold-associated 
acute inflammation in four patients with FCAS subjected to 
cold challenge. When subjected to cold challenge without 
anakinra treatment, the patients with FCAS developed low 
grade fever, rash, and arthralgia starting 1–2 hours after cold 
challenge. The patients with FCAS treated with anakinra 
before cold challenge did not develop any of the signs or 
symptoms that they had developed during the previous cold 
challenge. These patients did develop a mild rash after the 
initial dose, but had no symptoms after the second dose and 
remained symptom-free for 24–48 hours.30
Given that use of IL-1RA is relatively new, its efficacy 
and safety on a long-term basis is not well documented. 
Several studies have assessed the long-term effects of IL-1 
antagonists in different phenotypes of CAPS patients, includ-
ing NOMID/CINCA. Lepore et al demonstrated the long-
term effects and sustainability of control of inflammatory 
manifestations in ten CINCA patients who were followed 
for 26–42 months. They demonstrated complete control of 
the inflammatory manifestations, such as skin rash, arthritis/
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arthralgia, elevated acute-phase reactants, and inflammatory 
anemia for up to almost 5 years of follow-up. Continuous 
treatment with anakinra completely controlled some of the 
neurologic manifestations such as chronic meningitis and 
headache (although control of papilledema and amelioration 
of hearing loss was not achieved).36 In a study by Neven et al, 
the long-term effects of anakinra for up to 26–42 months 
have also been demonstrated in treating a broad range of 
systemic manifestations, neurologic involvement, and growth 
 parameters. The magnitude of these responses was dose-
dependent, with improvement in constitutional symptoms 
such as fever, rash, and arthralgia at 1 mg/kg/day. Higher 
doses (2–3 mg/kg/day) were necessary in five patients with 
persistent headache and papilledema after one year of therapy 
in order to achieve ongoing normalization of biologic inflam-
mation marker levels and decreases in central nervous system 
inflammation.10 However, central nervous system inflamma-
tion normalized in only one patient, with improvement and 
stabilization in a total of four patients. These data indicate 
that long-term remission is possible, but this is difficult to 
achieve in severe cases of NOMID.
Leslie et al also demonstrated a positive outcome in 
15 MWS patients followed for a median of 17 (1–39) 
months. All patients showed a sustained response to drug 
therapy without dosage adjustments to prevent recur-
rence of  symptoms. There was significant improvement 
in renal disease measured by scintigraphic scan for 
amyloidosis.34
Based on the studies to date, it is clear that anakinra is 
a major advance in the management of NOMID and other 
CAPS phenotypes. To date, there have been very few side 
effects demonstrated with administration of anakinra. Local 
injection site reactions, including itching, swelling and 
redness, have been reported to occur in 42% of patients.35 
Similar rates of local site reactions were reported in the 
other studies mentioned above.32–34 However, injection site 
reactions are uncommon after the first month of therapy. 
Despite the success of anakinra, the short half-life of 
4–6 hours requires daily subcutaneous injections. Treatment 
becomes a lifelong process, because drug withdrawal leads 
to disease flares. As discussed below, other IL-1-blocking 
agents with longer half-lives are also being developed and 
tested with success.
Rilonacept: iL-1 trap
Rilonacept, an IL-1 trap cytokine inhibitor, has been used 
effectively in the treatment of many diseases. Rilonacept utilizes 
cytokine trap technology, which allows for effective inhibition 
due to multicomponent “traps” containing binding sites for the 
cytokine as well as their accessory proteins. Cytokine traps have 
been very effective in autoinflammatory diseases because they 
bind to their respective cytokines with high affinity.37 Rilonacept 
was first approved by the US Food and Drug Administration 
in 2008 specifically for FCAS and MWS patients over the age 
of 11 years. The drug has a half-life of 8.6 days, which makes 
weekly injections an improvement over daily injections of anak-
inra. The safety and efficacy of weekly subcutaneous injections 
(160 mg/week) of rilonacept have recently been evaluated in 
patients with FCAS and MWS. The efficacy of treatment was 
confirmed in a one-year study, with five FCAS patients having 
confirmed mutations.38 All five patients showed improvement 
of symptoms, with the maximum improvement at days 6–10. 
All patients were given doses of 160 mg weekly, although 
remission did not occur in four patients, who were then given 
doses of 320 mg. All five patients tolerated the drug very well 
with no injection site reactions, and showed long-term efficacy 
at the 2-year follow-up.
In two sequential, double-blind, placebo-controlled tri-
als of patients with FCAS or MWS, all patients had posi-
tive CIAS1 gene mutations. In the first study, a randomized 
6-week trial, 47 patients received either rilonacept at a dose 
of 160 mg/week or placebo. The patients receiving the drug 
showed a decrease in disease activity score of 84% compared 
with 13% in patients receiving placebo. In the second study, 
patients were enrolled in a 9-week, single-blind treatment 
period followed by a 9-week, double-blind withdrawal period. 
Patients on rilonacept therapy during the “withdrawal” period 
demonstrated improved efficacy compared with the group on 
placebo.39 Patients treated with rilonacept had mild injection 
site reactions.
Canakinumab: iL-1β monoclonal antibody
Canakinumab is a human IL-1β monoclonal antibody with 
very good efficacy in the treatment of CAPS patients. It 
has a long half-life of 26 days, which allows for a dosing 
schedule of subcutaneous injections every 8 weeks. This 
dosing schedule is favorable compared with that of anakinra 
(daily) and rilonacept (weekly). Canakinumab was approved 
by the US Food and Drug Administration in 2009 for use in 
CAPS patients over 4 years of age. The first open-label clini-
cal trial for canakinumab was completed in 2008 in seven 
mutation-confirmed CAPS patients. In these patients, IL-1β 
production fell to levels similar to those seen in unaffected 
healthy controls after 8 weeks of therapy.40
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In another double-blind, randomized trial in 2008, 
35 CAPS patients (all with confirmed NLRP3 mutations), 
enrolled in a three-part, 48-week trial to receive 150 mg 
of canakinumab every 8 weeks. In the first part, 34 of 
the 35 patients had a complete response in as little as 
8 days, which was confirmed by physician assessment of 
disease activity and rash, as well as C-reactive protein and 
serum amyloid A levels. In the second part of the study, 
15 patients received the drug and 16 patients received 
placebo. All 15 patients in the treatment group experi-
enced remission of symptoms, while 13 of those in the 
placebo group experienced disease flares and increased 
C-reactive protein. In the third part, the 31 patients showed 
sustained clinical remission with minimal disease activity, 
disappearance of rash, and normalization of C-reactive 
protein and serum amyloid A levels. Complete remission 
was seen in 97% of the patients on treatment, and random-
ization to placebo led to disease flares in 81% of patients, 
whereas all patients who received the drug remained 
in remission. Injection site reactions occurred in up to 
9% of patients, and up to 14% of the patients developed 
vertigo.41
Side effects of biological  
modulators of IL-1/IL-1R
The primary side effects of anakinra in NOMID have been 
reported to be local injection site reactions, including red-
ness, rash, itchiness, or pain. Other skin reactions such 
as bruising or bleeding can occur, but are very rare. Skin 
reactions usually resolve after 1–2 weeks. Biological modu-
lators carry a risk of infection, and this has been reported 
when anakinra is used to treat rheumatoid arthritis but not 
NOMID. Other reactions may include headaches, vomiting, 
arthralgias, pyrexia, and nasopharyngitis. The most com-
mon side effects of canakinumab in the treatment of CAPS 
include nasopharyngitis, diarrhea, nausea, influenza, and 
headache. A similar side effect profile was also described 
with rilonacept, with injection site reactions being the most 
common adverse effect.
Discussion
Remarkable advances have been made in our understand-
ing of the molecular and genetic pathways responsible for 
the clinical phenotypes of NOMID. Studying patients with 
NOMID has allowed us to define the extent of disease dam-
age caused by overproduction and secretion of IL-1β due to 
mutations in the CIAS1 gene. The discovery of these gene 
mutations has led to major advances in the treatment of this 
rare disease and led to rapid resolution of its inflammatory 
manifestations. IL-1 blocking agents have been found to 
be helpful not only in NOMID and other milder forms of 
CAPS, but also in other IL-1-mediated diseases, such as 
familial Mediterranean fever, gout/pseudogout, osteoar-
thritis, rheumatoid arthritis, type 2 diabetes mellitus, 
pyoderma gangrenosum, and other diseases as noted in 
Table 2.  Numerous studies have shown positive effects of 
anakinra in patients with the above disorders.  Significant 
studies are described in Table 3. Anakinra offers an ideal 
treatment option for many of these diseases due to its 
excellent safety profile and ease of administration sub-
cutaneously or intravenously. The short half-life of 4–6 
hours offers an additional safety benefit and allows for 
short-term use.
Studies of patients with NOMID have been imperative 
in characterizing the extent of organ-specific inflammatory 
manifestations. The disease severity in NOMID is extreme 
and requires close monitoring of the involved organs and 
aggressive treatment to control both systemic and organ-
specific manifestations. It is important for patients with 
NOMsID to receive an early diagnosis and prompt treatment, 
because cumulative inflammation can lead to progressive and 
permanent organ damage. Lepore et al36 reported on patients 
who received an early diagnosis and prompt treatment, and 
had not shown any new disease-related manifestations such 
Table 2 examples of conditions treated by anakinra
Inflammatory diseases
 Gout and pseudogout
 Type 2 diabetes
 Pustular psoriasis
 Sjögren’s syndrome
Joint, bone, and muscle diseases
 Rheumatoid arthritis
 Ankylosing spondylitis
 erosive osteoarthritis of the hand
 Osteomyelitis
Hereditary systemic autoinflammatory disease
 Cryopyrin-associated periodic syndrome
 Hyper-igD syndrome
 Familial Mediterranean fever
 Periodic fever, aphthous stomatitis, pharyngitis, and adenitis
System inflammatory diseases
 Systemic juvenile idiopathic arthritis
 Adult onset Still’s disease
 Schnitzler syndrome
 Behçet’s disease
 Synovitis, acne, pustulosis, hyperostosis, osteitis
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as hearing loss, papilledema, chronic meningitis, or mental 
retardation. These observations illustrate the need for prompt 
recognition and treatment of all CAPS phenotypes, includ-
ing NOMID.
As demonstrated in the many studies of diseases treated 
by anakinra, the upstream mechanism or gene defect in a 
disease does not have as much influence as the downstream 
effects, including IL-1β overproduction. In NOMID syn-
drome, mutations in CIAS1 are found in about 50% of 
patients, and appear to be only one of the underlying genetic 
defects in this group of diseases. Recent studies suggest that 
treatment of patients with normal CIAS1 genetic sequencing 
may be successful by correction of the downstream effects 
(IL-1β overproduction) regardless of the upstream mecha-
nism (CIAS1 defect). This imbalance of IL-1β production 
can be alleviated by administration of anakinra. Anakinra 
has been shown to achieve rapid and sustained clinical 
remission for the majority of CAPS patients, including 
NOMID syndrome, and many other disease states.
Disclosure
The authors report no conflicts of interest in this work.
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